Premium
Objective measures of the efficacy of noninvasive positive‐pressure ventilation in amyotrophic lateral sclerosis
Author(s) -
Aboussouan Loutfi Sami,
Khan Saeed U.,
Banerjee Mousumi,
Arroliga Alejandro C.,
Mitsumoto Hiroshi
Publication year - 2001
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/1097-4598(200103)24:3<403::aid-mus1013>3.0.co;2-3
Subject(s) - amyotrophic lateral sclerosis , medicine , vital capacity , positive pressure ventilation , lung function , quality of life (healthcare) , cardiology , ventilation (architecture) , pulmonary function testing , anesthesia , physical therapy , lung , respiratory system , diffusing capacity , disease , mechanical engineering , nursing , engineering
The impact of noninvasive positive‐pressure ventilation (NIPPV) on pulmonary function studies, quality of life, and survival was assessed in patients with amyotrophic lateral sclerosis. NIPPV did not change the rate of decline of the forced vital capacity (FVC) and forced expiratory volume in the first second (FEV 1 ) (2.31 and 2.09 percent‐predicted points per month, respectively). NIPPV resulted in a drop of FEV 1 by 5.94 percent‐predicted points ( P = 0.07), and of maximal inspiratory pressure by 6.33 percent‐predicted points ( P = 0.11). The change in FEV 1 and FVC pre‐ and postintervention correlated with the corresponding change in maximal inspiratory pressure. Fatigue and mastery scores were improved by NIPPV. Median survivals in patients intolerant and tolerant of NIPPV were 5 and 20 months, respectively ( P = 0.002). Although NIPPV has no impact on the rate of decline of lung function and may have deleterious effects on spirometric measures, it may improve quality of life and survival. © 2001 John Wiley & Sons, Inc. Muscle Nerve 24: 403–409, 2001.